BioLineRx Ltd. (NASDAQ:BLRX) Sees Large Drop in Short Interest

BioLineRx Ltd. (NASDAQ:BLRX) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 827,800 shares, a drop of 10.2% from the November 30th total of 921,900 shares. Based on an average daily volume of 1,000,000 shares, the short-interest ratio is currently 0.8 days.

Analysts Set New Price Targets

A number of analysts recently commented on BLRX shares. HC Wainwright decreased their target price on BioLineRx from $21.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, November 25th. StockNews.com started coverage on shares of BioLineRx in a research note on Thursday, December 26th. They set a “hold” rating on the stock.

BioLineRx Trading Up 1.2 %

NASDAQ BLRX traded up $0.00 on Tuesday, hitting $0.21. The company’s stock had a trading volume of 1,393,354 shares, compared to its average volume of 529,682. The company has a current ratio of 1.52, a quick ratio of 1.37 and a debt-to-equity ratio of 2.11. BioLineRx has a 52-week low of $0.19 and a 52-week high of $1.59. The firm has a market cap of $17.11 million, a P/E ratio of -0.97 and a beta of 1.39. The company’s 50-day simple moving average is $0.33 and its 200 day simple moving average is $0.53.

Institutional Investors Weigh In On BioLineRx

Several hedge funds have recently added to or reduced their stakes in BLRX. CVI Holdings LLC bought a new position in BioLineRx during the 2nd quarter valued at about $462,000. PVG Asset Management Corp purchased a new stake in BioLineRx in the second quarter worth about $70,000. Finally, Atria Investments Inc lifted its position in shares of BioLineRx by 27.9% during the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 29,193 shares in the last quarter. 1.56% of the stock is owned by institutional investors.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.